文章摘要
基于PI3K/Akt/mTOR信号通路探讨复方骨疏康制剂对绝经后骨质疏松症的影响
投稿时间:2025-02-08  修订日期:2025-02-27
DOI:
中文关键词: PI3K/Akt/mTOR  复方骨疏康制剂  绝经后骨质疏松症  
英文关键词: 
基金项目:1、江西省中医药管理局科技计划项目--基于PI3K/Akt/mTOR信号通路探讨复方骨疏康制剂对绝经后骨质疏松症的影响(项目编号2023B1326) 2、江西科技学院校级自然科学项目--基于网络药理学和分子对接技术研究中药复方骨疏康对骨质疏松症的作用机制研究(项目编号ZR2113)。
作者单位邮编
荣小娟* 江西科技学院 330098
摘要点击次数: 26
全文下载次数: 0
中文摘要:
      摘要: 目的 评估复方骨疏康制剂对绝经后骨质疏松症的防治效果,并探讨相关机制。 方法 选取健康SD雌性小鼠50只,将其随机分为5组:假手术组、模型组、骨疏康低剂量组、骨疏康中剂量组、骨疏康高剂量组,各10只。测定各组小鼠股骨、椎骨骨密度;采用HE染色检测各组小鼠股骨骨小梁变化情况;采用Elisa法检测小鼠血清P1NP、β-CTX 的含量变化情况;采用免疫组化法检测胫骨组织中PI3K、Akt、mTOR蛋白表达情况。结果 与假手术组(0.39±0.03)、(0.28±0.03)相比,模型组股骨(0.16±0.03)、椎骨(0.13±0.02)骨密度下降,P<0.05;与模型组相比,复方骨疏康各剂量组股骨、椎骨骨密度增加,P<0.05;与假手术组(0.374±0.094)相比,模型组(0.274±0.023)骨小梁面积减少,P<0.05;与模型组相比,复方骨疏康各剂量组骨小梁面积增加,P<0.05;与假手术组(13.31±0.37)、(3.67±0.17)相比,模型组(9.56±0.17)、(4.39±0.20)P1NP含量减少而β-CTX含量增高,P<0.05;与模型组相比,复方骨疏康各剂量组P1NP含量逐渐增多而β-CTX含量逐渐减少,P<0.05;PI3K、Akt、mTOR在小鼠股骨组织中呈弥漫性表达,在假手术组表达最高,模型组表达最低,与模型组相比,骨疏康制剂低、中、高组表达逐渐升高。结论 复方骨疏康制剂能增加PMOP小鼠的骨密度、骨小梁面积、升高血清P1NP含量,同时降低血清β-CTX含量,免疫组化结果显示复方骨疏康制剂能使PI3K、Akt、mTOR在PMOP小鼠股骨中的表达升高,表明复方骨疏康制剂对PMOP小鼠具有防治作用,其防治机制可能是通过影响机体内PI3K/Akt/mTOR信号通路中的相关蛋白有关。
英文摘要:
      Abstract Objective: To investigate the preventive effect of compound gushukang preparation on postmenopausal osteoporosis and to explore the related mechanisms. Methods: Fifty healthy female wistar rats were selected and randomly divided into five groups: the sham operation group, the model group, the low-dose group of osteoporosis, the medium-dose group of osteoporosis, and the high-dose group of osteoporosis, 10 rats in each group. Bone density of femur and vertebrae was measured in each group; changes in trabecular bone of femur in each group were detected by HE staining; changes in serum P1NP and β-CTX were detected by Elisa assay; and protein expression of PI3K, Akt and mTOR in tibia tissues of each group was detected by immunohistochemical assay. Results:Compared with the sham-operated group (0.39±0.03) and (0.28±0.03), femur (0.16±0.03) and vertebrae (0.13±0.02) bone mineral density decreased in the model group, P<0.05; compared with the model group, femur and vertebrae bone mineral density increased in the compound osteoporosis group for each dose, P<0.05; compared with the sham-operated group (0.374±0.094), the model group (0.274±0.023), the area of bone trabeculae decreased, P<0.05; compared with the model group, the area of bone trabeculae increased in each dose group of Compound Osteoporosis, P<0.05; compared with the sham-operated group (13.31±0.37), (3.67±0.17), the model group (9.56±0.17), (4.39±0.20), the P1NP, β-CTX. Conclusion: Compound osteoporosis preparation can increase the bone mineral density, bone trabecular area, elevate the serum P1NP content, and reduce the serum β-CTX content of PMOP rats. The results of immunohistochemistry showed that compound osteoporosis preparation can elevate the expression of PI3K, Akt, and mTOR in the femur of PMOP rats, which suggests that the compound osteoporosis preparation has a preventive effect against PMOP rats, and its preventive mechanism may be related to the effect of PI3K, Akt, and mTOR signaling pathway in the organism. The mechanism of prevention may be through affecting the related proteins in the PI3K/Akt/mTOR signaling pathway in the organism. [Keywords] PI3K/Akt/mTOR; compound osteoporosis preparation; postmenopausal osteoporosis;
View Fulltext   查看/发表评论  下载PDF阅读器
关闭
手机扫一扫看
分享按钮